Publication:
Melatonin stimulates the nonamyloidogenic processing of βaPP through the positive transcriptional regulation of ADAM10 and ADAM17

dc.contributor.authorMayuri Shuklaen_US
dc.contributor.authorHtut Htut Htooen_US
dc.contributor.authorPhitchayapak Wintachaien_US
dc.contributor.authorJean Francois Hernandezen_US
dc.contributor.authorClaire Duboisen_US
dc.contributor.authorRolf Postinaen_US
dc.contributor.authorHuaxi Xuen_US
dc.contributor.authorFrédéric Checleren_US
dc.contributor.authorDuncan R. Smithen_US
dc.contributor.authorPiyarat Govitrapongen_US
dc.contributor.authorBruno Vincenten_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherInstitut des Biomolecules Max Mousseronen_US
dc.contributor.otherUniversite de Sherbrookeen_US
dc.contributor.otherJohannes Gutenberg Universitat Mainzen_US
dc.contributor.otherXiamen Universityen_US
dc.contributor.otherSanford Burnham Prebys Medical Discovery Instituteen_US
dc.contributor.otherUniversite Nice Sophia Antipolisen_US
dc.contributor.otherCNRS Centre National de la Recherche Scientifiqueen_US
dc.date.accessioned2018-11-23T09:51:24Z
dc.date.available2018-11-23T09:51:24Z
dc.date.issued2015-01-01en_US
dc.description.abstract© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. Melatonin controls many physiological functions including regulation of the circadian rhythm and clearance of free radicals and neuroprotection. Importantly, melatonin levels strongly decrease as we age and patients with Alzheimer's disease (AD) display lower melatonin than age-matched controls. Several studies have reported that melatonin can reduce aggregation and toxicity of amyloid-β peptides that are produced from the β-amyloid precursor protein (βAPP). However, whether melatonin can directly regulate the βAPP-cleaving proteases ('secretases') has not been investigated so far. In this study, we establish that melatonin stimulates the α-secretase cleavage of βAPP in cultured neuronal and non-neuronal cells. This effect is fully reversed by ADAM10- and ADAM17-specific inhibitors and requires both plasma membrane-located melatonin receptor activation, and ERK1/2 phosphorylation. Moreover, we demonstrate that melatonin upregulates both ADAM10 and ADAM17 catalytic activities and endogenous protein levels. Importantly, genetic depletion of one or the other protease in mouse embryonic fibroblasts prevents melatonin stimulating constitutive and PKC-regulated sAPPα secretion and ADAM10/ADAM17 catalytic activities. Furthermore, we show that melatonin induces ADAM10 and ADAM17 promoter transactivation, and we identify the targeted promoter regions. Finally, we correlate melatonin-dependent sAPPα production with a protection against staurosporine-induced apoptosis. Altogether, our results provide the first demonstration that melatonin upregulates the nonamyloidogenic ADAM10 and ADAM17 proteases through melatonin receptor activation, ERK phosphorylation and the transactivation of some specific regions of their promoters and further underline the preventive rather than curative nature of melatonin regarding AD treatment.en_US
dc.identifier.citationJournal of Pineal Research. Vol.58, No.2 (2015), 151-165en_US
dc.identifier.doi10.1111/jpi.12200en_US
dc.identifier.issn1600079Xen_US
dc.identifier.issn07423098en_US
dc.identifier.other2-s2.0-84922771460en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/35638
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84922771460&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.titleMelatonin stimulates the nonamyloidogenic processing of βaPP through the positive transcriptional regulation of ADAM10 and ADAM17en_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84922771460&origin=inwarden_US

Files

Collections